Finance

Senarai
HBMN:SWX
HBM Healthcare Investments AG
CHF 223.00
+0.22%
(+0.50) 1H
18 Nov, 5:31:03 PTG GMT+1  ·   CHF
Semua simbol
SimbolHargaPerubahan% Perubahan
Menjana cerapan popular untuk HBMN...
Buka
CHF 222.50
Tinggi
CHF 223.50
Rendah
CHF 219.50
Permodalan Pasaran
1.48B
Purata volum
5.81K
Volum
9.03K
Dividen
4.04%
Dividen suku tahunan
CHF 2.25
Tarikh tanpa dividen
17 Jun 2026
Nisbah H/P
4.19
tgi 52 mgu
CHF 258.00
rdh 52 mgu
CHF 198.60
EPS
CHF 53.19
Syer tertunggak
6.62J
Buka
CHF 222.50
Tinggi
CHF 223.50
Rendah
CHF 219.50
Permodalan Pasaran
1.48B
Purata volum
5.81K
Volum
9.03K
Dividen
4.04%
Dividen suku tahunan
CHF 2.25
Tarikh tanpa dividen
17 Jun 2026
Nisbah H/P
4.19
tgi 52 mgu
CHF 258.00
rdh 52 mgu
CHF 198.60
EPS
CHF 53.19
Syer tertunggak
6.62J
Cerita berita
Daripada sumber web dan rakan kongsi berita
Profil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health. A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities. Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Perihal HBM Healthcare Investments AG
CEO-
Pekerja-
Diasaskan12 Jul 2001
Ibu pejabatZug, Zug, Switzerland
SektorFinancials
Industri-
Laporan terakhir
23 Okt 2026
Tempoh fiskal
S2 2027
- / -
Hasil / Anggaran (CHF)
-60.69J / -
Panggilan persidangan pendapatan fiskal Suku Ke-2 2027
Menunggu panggilan persidangan pendapatan
Sekilas pandang
Cerapan daripada berita dan laporan terkini
Laporan sebelumnyaSemua nilai dalam CHF
Loading Previous Earnings...
Hasil
Pendapatan bersih
Semua nilai dalam CHF
Dis 2025
Mac 2026
Jun 2026
Sep 2026
Hasil
191.76J
-13.57J
239.30J
-60.69J
Kos barangan yang dijual
-
-
-
-
Kos hasil
-
-
-
-
Perbelanjaan penyelidikan dan pembangunan
-
-
-
-
Jumlah perbelanjaan penyelidikan dan pembangunan
-
-
-
-
Perbelanjaan jualan, am dan pentadbiran
395.00K
397.00K
395.00K
396.00K
Belanja kendalian
575.00K
671.00K
653.00K
583.00K
Jumlah belanja kendalian
575.00K
671.00K
653.00K
583.00K
Pendapatan kendalian
191.18J
-14.24J
238.65J
-61.27J
Pendapatan bukan kendalian lain
-
-
-
-
EBT termasuk item luar biasa
190.85J
-14.57J
238.32J
-61.61J
EBT tidak termasuk item luar biasa
190.85J
-14.57J
238.32J
-61.61J
Belanja cukai pendapatan
-
-
-
-
Kadar cukai berkesan
-
-
-
-
Belanja kendalian lain
180.00K
274.00K
258.00K
187.00K
Pendapatan bersih
190.85J
-14.57J
238.32J
-61.61J
Margin untung bersih
99.53%
107.36%
99.59%
101.52%
Perolehan bagi setiap syer
-
-
-
-
Pendapatan faedah dan pelaburan
-
-
-
-
Belanja faedah
-328.00K
-328.00K
-331.00K
-339.00K
Belanja faedah bersih
-328.00K
-328.00K
-331.00K
-339.00K
Caj susut nilai dan pelunasan
-
-
-
-
EBITDA
-
-
-
-
Keuntungan atau kerugian daripada jualan aset
-
-
-
-
Acara akan datang
Kandungan AI boleh mengandungi kesilapan. Ketahui lebih lanjut
BantuanHantar maklum balasPrivasiSyaratPenafian
Apl Google